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Background
The elicitation of broadly neutralizing antibodies (Nabs)
remains one of the most challenging goals in HIV-1 vac-
cine development. Some HIV-1 infected individuals
present virus specific broadly neutralizing activity in their
serum, proving that the desired Nabs can indeed be elic-
ited in vivo. However, attempts to elicit this response in
animal models using HIV-envelope based immunogens
have failed so far. Still, we believe that viral variants with
specific envelope properties may elicit these antibodies if
formulated into an appropriate vaccine immunogen.
The aim of this study is to characterize the phenotype of
HIV-1 variants obtained from acute HIV infection cases
and to investigate their neutralization sensitivity to the
patient's own sera and to a panel of monoclonal antibod-
ies as to identify HIV-1 variants eliciting specific broadly
Nabs.
Methods
Viruses obtained by biological cloning at different time
points from pre-seroconversion throughout follow-up
were tested for co-receptor usage with U87.CD4 glioma
cells expressing wild type (CCR5 or CXCR4) or chimeric
receptors. A full neutralization sensitivity pattern was
achieved by testing a series of clones against the serum
samples collected throughout follow-up of the patient,
heterologous sera, and the monoclonal antibodies 2F5,
4E10, and 2G12.
Results
Results showed that clones isolated early in infection were
able to use the wild type CCR5 receptor and none of the
chimeric receptors or CXCR4. Virus phenotypic variation
is detectable only several months later when clones able
to infect also chimeric receptors emerge. The development
of HIV-1 Nabs occurred several months after seroconver-
sion, and increased as to fully neutralize the original early
virus in about 1 year.
Conclusion
These results suggest a relation between the increase of
variability and the onset of a neutralizing response.
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